News

GSK, Pfizer and CureVac

CureVac and GSK settle mRNA patent dispute with Pfizer and BioNTech
Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the mRNA vaccine technology that was at the forefront of the world's fight against COVID-19.
Pfizer, BioNTech reach Covid jab settlement with GSK, CureVac
American pharmaceutical giant Pfizer and German biotech firm BioNTech will pay Britain s GSK and Germany s CureVac $740 million
GSK and CureVac settle mRNA patent spat with Pfizer/BioNTech
The complicated legal wrangling has been brought to a close after CureVac and BioNTech settled their mRNA patent litigation in the US – in the wake of BioNTech's recent agreement to acquire its former rival in a $1.25 billion deal.
CureVac settles mRNA patent dispute litigation with Pfizer and BioNTech
(Reuters) -German drugmaker CureVac and GSK reached an agreement with BioNTech and Pfizer on Thursday to resolve a years-long patent dispute related to mRNA-based COVID-19 vaccines, CureVac said. As part of the settlement,
GSK collects $320M as BioNTech, Pfizer settle mRNA patent spat with CureVac
The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the vaccine technology continue to play out on several other fronts. | Pfizer and BioNTech have settled an mRNA patent lawsuit originally brought by CureVac in the U.
BioNTech settles Covid-19 patent dispute with CureVac
BioNTech has agreed to pay UK drugmaker GSK royalties on its Covid-19 and influenza vaccines as part of a patent settlement with CureVac, in a deal that allows the biotech to move forward with the purchase of its German rival.
GSK to Receive $370 Million in U.S. Patent Litigation Settlement
The pharma giant will also receive a 1% royalty on future U.S. sales of influenza, Covid-19 and other related combination mRNA vaccine products made by BioNTech and Pfizer.
GSK, CureVac to receive $740M as COVID vaccine patent dispute with Pfizer, BioNTech settled
CureVac (CVAC) and GSK (GSK) to receive $740M and other payments in a settlement with Pfizer (PFE) and BioNTech (BNTX) over mRNA vaccine patents. Read more here.
GSK to be paid up to £370 million after patent row settles in US
CureVac – a German pharmaceutical company – settled a long-running patent dispute with rival BioNTech and Pfizer in the US on Thursday.
Pfizer, McDonald’s, Intel, Apple: Stocks That Defined the Week
The Score is a weekly review of the biggest stock moves and the news that drove them. Here is this week's installment: ...
1 Reason to Buy Pfizer (PFE) Stock
And better still, healthy and growing dividend-paying stocks tend to increase their payouts over time. Pfizer's total annual ...
Pfizer raises 2025 profit forecast as cost-cutting program gains traction
Pfizer said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting ...
Buy Pfizer Stock At $24?
Investor sentiment has been adversely affected by worries regarding the company’s drug pipeline. Nonetheless, we believe PFE ...
Medical Marketing & Media13h
Rx Rundown: Pfizer, SERB Pharmaceuticals, Novo Nordisk and more
SERB Pharmaceuticals plans to buy Y-mAbs Pharmaceuticals in a $412 million all-cash deal. CorMedix bought Melinta ...
Pfizer Raises Profit Outlook Despite Uncertainty Over Tariffs, Drug Prices
Chief Executive Albert Bourla says he is hopeful about finding a solution in response to Trump’s demand for price cuts.
Pfizer CEO attending $25 million fundraiser at Trump's golf club after president demands drug price cuts, sources say
Pfizer CEO Albert Bourla is expected at a pro-Trump fundraiser on Friday, sources told CBS News, one day after the president ...
Pfizer's Turnaround Has Truly Started (Earnings Update)
Pfizer delivered a strong Q2 earnings beat, raising FY2025 guidance and demonstrating effective cost-cutting. Learn why PFE ...